Cargando…
RIVAroxaban TWICE daily for lysis of thrombus in the left atrial appendage in patients with non-valvular atrial fibrillation: the RIVA-TWICE study
INTRODUCTION: Rivaroxaban is a direct factor Xa inhibitor used once a day for prevention of thrombotic events in patients with atrial fibrillation (AF). However, in a small proportion of subjects thrombus in the left atrial appendage (LAA) is present despite this treatment. The aim of this study was...
Autores principales: | Piotrowski, Roman, Zaborska, Beata, Pilichowska-Paszkiet, Ewa, Sikora-Frąc, Małgorzata, Baran, Jakub, Kułakowski, Piotr |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069443/ https://www.ncbi.nlm.nih.gov/pubmed/32190138 http://dx.doi.org/10.5114/aoms.2019.86616 |
Ejemplares similares
-
Subclinical Dysfunction of Left Atrial Compliance after Cryoballoon versus Radiofrequency Ablation for Paroxysmal Atrial Fibrillation
por: Pilichowska-Paszkiet, Ewa, et al.
Publicado: (2023) -
Iatrogenic Arteriovenous Fistula and Atrial Septal Defect Following Cryoballoon Ablation for Atrial Fibrillation – Two Correctable Causes of Right Heart Failure
por: Dudzińska-Szczerba, Katarzyna, et al.
Publicado: (2019) -
Echocardiographic assessment of left atrial function for prediction of efficacy of catheter ablation for atrial fibrillation
por: Pilichowska-Paszkiet, Ewa, et al.
Publicado: (2021) -
The Role of Galectin-3 in Heart Failure—The Diagnostic, Prognostic and Therapeutic Potential—Where Do We Stand?
por: Zaborska, Beata, et al.
Publicado: (2023) -
Successful Resolution of a Large Left Atrial and Left Atrial Appendage Thrombus with Rivaroxaban
por: Gaznabi, Safwan, et al.
Publicado: (2019)